INTRODUCTION 77
Staphylococcus aureus is a nosocomial and community-acquired pathogen, 78 which causes several diseases, ranging from minor skin infections to serious life-79 threatening wound infections, bacteraemia, endocarditis, pneumonia and toxic shock 80 syndrome (25). The potential of S. aureus to develop multidrug resistance to 81 traditional antibiotics has created renewed interest in using alternative treatment 82 options such as antibody-based immunotherapy approaches (5, 19, 31, 34). The key 83 factor for developing an anti-staphylococcal immunotherapy depends on the 84 identification of those bacterial antigens expressed in vivo that provide protection by 85 the immune system of a wide patient population during infection (9). Therefore, 86 several studies have investigated the immune response to S. aureus to determine 87 which bacterial antigens are associated with protective anti-staphylococcal antibodies 88 (4, 7, 9, 24, 27, 39). However, the significance and specificity of the immune 89 response in S. aureus infections proved difficult to be elucidated as a number of 90 clinical trials have recently failed (34). Other immunotherapy approaches target 91 typical virulence factors, which may play a central role in the pathogenesis of 92 staphylococci (2, 3, 10, 12, 18, 20, 22, 27, 37, 43, 44). But, functional redundancy of 93 adhesion proteins or the appearance of escape mutants may limit the efficacy of 94 strict monovalent immunotherapeutic strategies. Some evidence suggests that also 95 bacterial cell wall components with immunogenic properties can serve as potential 96 candidates for immunotherapy development (16, 21) . 97
One such protein involved in cell wall metabolism is the immunodominant 98 staphylococcal antigen A (IsaA). IsaA is a highly immunogenic, non-covalently cell 99 wall bound, lytic transglycosylase (24, 36, 38) which is co-regulated with a 100 glycylglycine endopeptidase, LytM (8). Strains of S. aureus lacking IsaA expression 101 are viable and the paralogue SceD, a second lytic transglycosylase, is able to 102 culture was centrifuged for 5 min at 13,000 x g. The washed bacterial sediment was 180 suspended in 1 ml PBS (10 mM sodium phosphate (pH 7.2), 0.15 M sodium 181 chloride). An aliquot of the cell suspension (100 µl) was mixed with UK-66P in PBS 182 and incubated at room temperature for 15 min. Then five µl of FITC-conjugated goat 183
anti-mouse IgG (H+L chain) (Dianova, Hamburg, Germany) was added, and the 184 mixture was incubated at room temperature for 30 min in a dark and moisture 185 produced reactive oxygen metabolites were analyzed. For that purpose, a negative 208 control sample was used to set a marker (M1) for fluorescence-1 (FL1) so that less 209 than 1% of the events were positive. In the study samples, the numbers of events 210 above this marker position were counted. Cells were analysed with a FACSCalibur 211 flow cytometer using CellQuestPro and WinMDI 2.9. 212
213

Neutrophil intracellular survival assay 214
Intracellular survival assays were performed as follows. Bacterial cultures 215
were washed twice in PBS, adjusted to 5×10 7 cfu and mixed with 100 µl whole 216 mouse blood and then incubated at 37° C in a water shaker. Before co-incubation, 217 bacteria were opsonized with UK-66P antibody (0.6 mg/ml) or isotype control 218 antibody (IC, dose equivalent) for 20 min at room temperature. Gentamicin (final 219 concentration 400 µ g/ml) and lysostaphin (final concentration 100 µ g/ml) were added 220 after 45 min to kill extracellular bacteria. At 60 min, the content of samples were 221 withdrawn, centrifuged to pellet the neutrophils, and washed to remove the antibiotic 222 medium. Neutrophils were then lysed in 1% saponin, and cfu calculated by plating on 223
TSB. 224 225
Catheter-related generalized infection in mice 226
The Ethics Committee of the Lower Franconia authorities endorsed all animal 227 studies. Age, gender and weight matched NMRI mice (Charles River, Sulzfeld, 228 Germany) were used in the experiment. Mice were intraperitoneally anaesthetised 229 with xylazin (8 mg/kg body weight) and ketamine (100 mg/kg body weight) and a 230 central venous catheter was surgically placed as already described (23). Twenty-four 231 hours after surgery the mice were inoculated via the catheter with 100 µl of a S. 232 aureus suspension, containing 1x10 7 cfu S. aureus bacteria. The bacterial 233 suspension was allowed to dwell within the catheter lumen for 15 min. The content of 234 the catheter was then flushed with 0.2 ml 0.9 % saline. Treated mice received 235 intravenously UK-66P (double dose regimen: 15 mg/kg in a volume of 100 µl 236
immediately and 24 h after bacterial challenge) and control mice received isotype 237 match antibody. Body weight and general appearance was assessed daily during the 238 experiment. Five days post inoculation the mice were euthanized by CO 2 inhalation. 239
Aseptically harvested organs were homogenized in 2 ml saline. Furthermore, the 240 location of the catheter in the superior vena cava was confirmed and the explanted 241 
Functional characterization of UK-66P 299
The monoclonal antibody UK-66P was selected for further studies based on its 300 high binding affinity to rIsaA. UK-66P was determined to be of IgG1 subclass and 301 indirect immunofluorescence on viable S. aureus showed its ability to bind to the cell 302 surfaces exposed IsaA antigen. Strain MA12, the isogenic IsaA knockout strain MA12 303 ∆ isaA and a protein A knockout strain Cowan I ∆ spa were used for staining. Bacteria 304 were incubated with UK-66P followed by fluorescein-labeled anti-mouse Ig and 305 binding of UK-66P to the bacterial surface was visualized by fluorescence 306 microscopy ( Fig. 2A-2C ). Viable cells of S. aureus MA12 interacted with the IsaA 307 specific monoclonal antibody UK-66P, while the IsaA mutant strain did not interact, 308
as demonstrated by lack of fluorescence on these cells. The S. aureus protein A 309 knock out strain also bound UK-66P indicating no cross-reactivity with protein A. 310
The targeted IsaA antigen is found conserved among all sequenced 311 methicillin-sensible and methicillin-resistant staphylococcal strains. Subsequently, 312 binding of UK-66P was exemplary tested to a collection of seven representative 313 isolates including strain ANS46 (SCCmec III), strain BK2464 (SCCmec II), strain 314 HDE288 (SCCmec IV), strain MU50 (vancomycin-resistant S. aureus (VRSA)), strain 315 MW2 (CA-MRSA), strain USA300 (CA-MRSA) and strain EMSRA-15 (epidemic 316 MRSA). UK-66P reacted with IsA of all tested strains, as verified by Western blotting 317 analysis (Fig. 2D) . 318 319
UK-66P mediate activation of professional phagocytes 320
As the monoclonal antibody UK-66P recognizes IsaA on the surface of S. 321 aureus, secondary experiments were performed to determine if the antibody UK-66P 322 could also act as an opsonizing agent resulting in the engulfment of bacteria by 323 activated neutrophils. To quantify phagocytosis, we scored the percentage of 324 oxidizing neutrophils. Neutrophils in whole mouse blood were co-incubated with 325 either wild-type or IsaA mutant S. aureus in the presence of UK-66P, isotype control 326 antibody (IC) or saline at 30 and 60 min (Fig. 3A-3B ). At both time points, the fraction 327 of oxidizing neutrophils was significantly higher after co-incubation of wild-type 328 bacteria with UK-66P than for the isotype control co-incubated bacteria (Mann-329 Whitney P < .05). More precisely, in the presence of UK-66P (0.6 mg/ml), 46.1% and 330 97.7% of neutrophils were activated during a co-incubation period of 30 and 60 min, 331 respectively (Fig. 3A) . The mean percentage of oxidizing neutrophils was 20.9% and 332 55.2% with IC after 30 and 60 min incubation time. In the absence of antibodies 333 (saline), the mean percentage of oxidizing neutrophils was 11.8% and 45.5% after 334 incubation time of 30 min and 60 min. Specificity controls followed the same 335 experimental setup except for using IsaA mutant S. aureus (Fig. 3B ). Under these 336 conditions, no UK-66P-dependent increase in the percentage of activated neutrophils 337 was detectable when compared to IC and saline primed neutrophils. In conclusion, in 338 the presence of UK-66P (0.6 mg/ml), 8.8% and 56% of neutrophils were activated 339 during a co-incubation period of 30 and 60 min, respectively (Fig. 3B) . The mean 340 percentage of oxidizing neutrophils was 24.8% and 66.2% with IC after incubation 341 time of 30 and 60 min. In the control incubated with saline, the mean percentage of 342 oxidizing neutrophils was 21% and 53% after incubation time of 30 and 60 min. Mann-Whitney P = .029; Fig. 4A and 4C) . Furthermore, the production of superoxide 357 was dose-dependent as half of the UK-66P dose (0.3 mg/ml) did not significantly 358 increase the oxidation quantity compared to IC (MFI, 564 and 366; Mann-Whitney P 359 = .057 Fig. 4A and 4C) . The UK-66P-dependent specificity was demonstrated by 360 failure to produce a significant potentiation of oxidative burst following co-stimulation 361 with the mutant S. aureus strain lacking IsaA expression. The level of oxidative burst 362 was equal to isotype control opsonized or non-opsonized (saline) mutant bacteria, 363 with a MFI of 284 and 287 for UK-66P at dose of 0.3 and 0.6 mg/ml, 294 for IC and 364 290 for saline (Fig. 4B and 4C) . Altogether, the oxidative burst activity per neutrophil 365 stimulated with wild-type S. aureus in the presence of adequate UK-66P was 366 approximately two-fold higher than that of the controls. These results suggest that 367 UK-66P is not only an activator for professional phagocytes but also a stimulus for 368 oxidative burst activity in a dose-dependent fashion. 369
370
Effect of UK-66P on the bactericidal activity of professional phagocytes to S. 371 aureus 372
Using an ex vivo system we determined if the increased oxidant activity of UK-373 66P translates to enhanced bacterial killing by innate immune mechanism. After the 374 addition of either UK-66P or IC opsonized wild-type and IsaA mutant S. aureus to 375 100 µl whole mouse blood for 30 min, samples were plated to enumerate survivors 376 after neutrophil lysis. The initial inoculum applied consisted of 5x10 7 bacteria. 377
Opsonization of bacteria with UK-66P significantly enhances bacterial killing by whole 378 blood neutrophils compared to IC opsonized bacteria (mean cfu ± SD, 1.13x10 5 ± 379 9.38x10 3 and 2.99x10 5 ± 3.65x10 3 ; Mann-Whitney P = .0286; Fig. 5 ). This effect was 380 not explainable by differences in the phagocytosis rate, since uptake of the wild-type 381
S. aureus was fairly comparable in the presence of either UK-66P or IC antibodies 382
(data not shown). Therefore, differences in phagocytotic killing were clearly 383 attributable to binding of UK-66P to IsaA, since UK-66P and IC treated IsaA mutant 384 S. aureus produced similar results (mean cfu ± SD, 1.8x10 5 ± 1.3x10 4 and 1.9x10 5 ± 385 6.1x10 3 ; Fig. 5 ). 386
Therapeutic efficacy of UK-66P in a catheter-related sepsis model 388
In order to stress the importance of the ex vivo results we tested the 389 therapeutic efficacy of UK-66P in a sublethal catheter-related sepsis model in mice. 390
Bacterial challenge and treatment was executed 24h after microsurgical implantation 391 of a catheter into the internal jugular vein of mice. Animals with weight loss greater 392 than 5% after surgery compared to baseline values were excluded from the study to 393 avoid compounding effects of anaesthesia or surgical preparation. All elected mice 394 were challenged with 1x10 7 cfu S. aureus MA12 via the catheter. Mice were then 395 treated via the catheter with UK-66P (N = 7; double dose regimen: 15 mg/kg in a 396 volume of 100 µl immediately and 24 h after bacterial challenge to yield an effective 397 dose of 30 mg/kg) or IC (N = 9; dose and volume equivalent). Mice were sacrificed 398 five days after S. aureus challenge. Numbers of viable bacteria in the liver, lung, 399 heart, spleen and kidneys following therapy with either UK-66P or IC were 400 quantitated and graphed against time postinfection (Fig. 6 ). In addition, the catheters 401 were collected and indwelling bacteria obtained.
Isotype control antibody treated 402 mice preferentially colonized the kidneys over the infection period. Analysis of the 403 bacterial load in this organ system revealed a significant difference in the numbers of 404 recovered wild-type S. aureus after UK-66P or IC treatment ( P < .05; Kruskal-Wallis 405 test with Dunn's posttest), with a greater recovery of bacteria in IC-treated animals. 406
The protective effect of the UK-66P treatment was approximately three logs. In 407 contrast, the lung, liver, heart and spleen cfu did not differ between UK-66P and IC 408 treated mice. The specific infection burden within each organ system is presented in 409 antibody treatment in wild-type S. aureus USA300 and MA12 had no effect with 57% 427 and 75% mortality rate, respectively over study period (Fig. 7) . In contrast, UK-66P 428 treatment protected against challenge with S. aureus USA300 (0% mortality rate; 429
Log-Rank/Mantel-Cox P = .038) and S. aureus MA12 (25% mortality rate; Log-430 Rank/Mantel-Cox P = .041). Clearly, the immunotherapeutic potential of UK-66P was 431 demonstrated by the fact that mice challenged with S. aureus MA12 ∆ isaA were not 432 protected by anti IsaA antibodies compared to isotype control treated mice (50 and 433 38% mortality rate; Log-Rank/Mantel-Cox P = .55). These results suggest that 434 
